Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting NCT07295704 Sponsor: The General Authority for Teaching Hospitals and Institutes Condition: Retinal Vein Occlusion and Diabetic Macular Oedema
Back to Retinal Vein Occlusion

Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting

NCT07295704
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older, of any sex
  • People who have been diagnosed with either type 1 or type 2 diabetes
  • People whose vision in the affected eye is at least 20/400 (with the best possible glasses or contact lens correction)
  • People who have diabetic macular edema (swelling in the central part of the retina) of a specific size — the trial site will measure this using a specialised eye scan called OCT, with the swelling falling within a defined range
  • People who have diabetic changes to the retina at any stage that is non-proliferative (early-to-moderate), or who have more advanced retinal disease that has been treated with a full course of laser therapy and shows no signs of current active disease on a specialised eye imaging test

Who may not be able to join:

  • People who only have functional vision in one eye
  • People who have chronic kidney failure or have had a kidney transplant due to diabetes-related kidney disease
  • People whose blood sugar control measure (HbA1c) is above 10%, indicating poorly controlled blood sugar levels
  • People who have a condition where the gel inside the eye is pulling on the central retina (vitreomacular traction syndrome)
  • People who have scar tissue growing on the surface of the retina (epiretinal membrane)
  • People who have had laser treatment to the retina (PRP) within the four months before the trial treatment
  • People who have had any eye surgery — including cataract surgery or surgery inside the eye — within the six months before the trial
  • People who have abnormal new blood vessels growing on the iris (the coloured part of the eye)
  • People who have severe glaucoma (a serious pressure-related eye condition)
  • People who have high-risk advanced diabetic retinal disease
  • People whose pupils do not dilate (widen) adequately for examination
  • People who have an enlarged avascular zone in the central retina (an area without normal blood vessels), as detected on eye imaging (confirm with trial site)
  • People who have any condition that could affect the accuracy of eye scan measurements or vision testing

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 00201026808348

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The General Authority for Teaching Hospitals and Institutes
Registry
ClinicalTrials.gov
Start date
15 October 2025
Est. completion
30 March 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change of best-corrected visual acuity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov